New drug ravulizumab tracked in Real-World MG study

NCT ID NCT06909253

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 21 times

Summary

This study follows 50 adults in Poland with generalized myasthenia gravis (gMG) who are taking ravulizumab for the first time. Researchers will track how well the drug improves daily activities and symptoms over time. The goal is to see how ravulizumab works in real-world settings, not in a controlled trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS, GENERALIZED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Bydgoszcz, Poland

  • Research Site

    RECRUITING

    Gdansk, Poland

  • Research Site

    RECRUITING

    Katowice, Poland

  • Research Site

    NOT_YET_RECRUITING

    Katowice, Poland

  • Research Site

    RECRUITING

    Krakow, Poland

  • Research Site

    RECRUITING

    Lodz, Poland

  • Research Site

    RECRUITING

    Lublin, Poland

  • Research Site

    WITHDRAWN

    Poznan, Poland

  • Research Site

    NOT_YET_RECRUITING

    Poznan, Poland

  • Research Site

    RECRUITING

    Szczecin, Poland

  • Research Site

    NOT_YET_RECRUITING

    Szczecin, Poland

  • Research Site

    RECRUITING

    Warsaw, Poland

  • Research Site

    RECRUITING

    Wroclaw, Poland

Conditions

Explore the condition pages connected to this study.